Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 4/20 | 0.48 |
| ▸ | KHK | P50053 | 11/20 | 0.40 |
| ▸ | MERTK | Q12866 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4071303 | 0.94 | HTR6 (0.45) | HTR6KHKTP53MAPTSMN1; SMN2 | |
| SCHEMBL4073460 | 0.88 | HTR6 (0.46) | HTR6TP53MAPT | |
| SCHEMBL4074381 | 0.88 | HTR6 (0.46) | HTR6KCNH2 | |
| SCHEMBL4073972 | 0.87 | HTR6 (0.46) | HTR6KHKMAPT | |
| SCHEMBL4066407 | 0.82 | HTR6 (0.54) | HTR6TP53MAPT | |
| SCHEMBL4075648 | 0.81 | HTR6 (0.42) | HTR6KHKKDM4EALDH1A1HPGD | |
| SCHEMBL4072753 | 0.78 | HTR6 (0.52) | HTR6CNR2 | |
| SCHEMBL4813478 | 0.77 | HTR6 (0.41) | HTR6MERTK | |
| SCHEMBL4818155 | 0.76 | HTR6 (0.41) | HTR6KHKMERTK | |
| SCHEMBL27630666 | 0.76 | HTR6 (0.41) | HTR6KHKMERTKCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1668590-A | 1-heterocyclylalkyl-3-sulfonyl-indole or -indazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH CORP (US) | 2005-09-14 | — | — | CN | claimed |
| US-7589108-B2 | 1-Heterocyclylalkyl-3-sulfonylindole or -indazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2009-09-15 | — | — | US | disclosed |
| CN-100351236-C | 1-heterocyclylalkyl-3-sulfonyl-indole derivatives as 5-hydroxytryptamine-6 ligands, process for their preparation and their use | WYETH CORP (US) | 2007-11-28 | — | — | CN | disclosed |
| US-20060030593-A1 | 1-Heterocyclylalkyl-3-sulfonylindole or -indazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2006-02-09 | — | — | US | disclosed |
| US-6995176-B2 | 1-heterocyclylalkyl-3-sulfonyl-indole or -indazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2006-02-07 | — | — | US | disclosed |
| CN-1668590-A | 1-heterocyclylalkyl-3-sulfonyl-indole or -indazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH CORP (US) | 2005-09-14 | — | — | CN | disclosed |
| US-20040024023-A1 | 1-Heterocyclylalkyl-3-sulfonyl-indole or -indazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH | 2004-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030593-A1 | 1-Heterocyclylalkyl-3-sulfonylindole or -indazole derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR3A, HTR5A | HTR6 1/4885KHK 3604/4885MERTK 1944/4885 |
| US-20040024023-A1 | 1-Heterocyclylalkyl-3-sulfonyl-indole or -indazole derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR3A, HTR1A | HTR6 1/4885KHK 3160/4885MERTK 1724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.